[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors

EJNMMI Research

Table 1 BP _ND of [ ¹¹ C]AF150(S) before and after treatment with various muscarinic agents

Brain region	Xanomeline		Xanomeline		Pirenzepine		Trihexyphenidyl		Darifenacin		Mean
	(5 mg kg ⁻¹SC)		(30 mg kg ⁻¹SC)		(30 mg kg ⁻¹SC)		(3 mg kg ⁻¹SC)		(3 mg kg ⁻¹IV)		(n= 20)
	Baseline	Pre-treated	Baseline	Pre-treated	Baseline	Pre-treated	Baseline	Pre-treated	Baseline	Pre-treated	Baseline
Left striatum	0.25 ± 0.05	0.30 ± 0.04^*	0.22 ± 0.07	0.22 ± 0.05	0.25 ± 0.04	0.21 ± 0.05^*	0.24 ± 0.02	0.21 ± 0.01	0.29 ± 0.03	0.28 ± 0.04	0.25 ± 0.05^a
Right striatum	0.24 ± 0.04	0.27 ± 0.01	0.23 ± 0.08	0.25 ± 0.06	0.25 ± 0.06	0.23 ± 0.03	0.22 ± 0.01	0.22 ± 0.01	0.26 ± 0.05	0.26 ± 0.03	0.24 ± 0.05^b
Hippocampus	0.20 ± 0.03	0.24 ± 0.01^*	0.19 ± 0.04	0.19 ± 0.06	0.20 ± 0.03	0.18 ± 0.02	0.19 ± 0.01	0.16 ± 0.01^**	0.24 ± 0.02	0.22 ± 0.04	0.20 ± 0.03^c
Frontal cortical area	0.12 ± 0.07	0.10 ± 0.04	0.17 ± 0.06	0.14 ± 0.04	0.16 ± 0.05	0.10 ± 0.04^**	0.11 ± 0.03	0.05 ± 0.03^*	0.22 ± 0.02	0.20 ± 0.06	0.16 ± 0.06^d
Posterior cortical area	0.12 ± 0.06	0.10 ± 0.04	0.15 ± 0.06	0.13 ± 0.04	0.13 ± 0.03	0.09 ± 0.03^**	0.11 ± 0.05	0.05 ± 0.03^*	0.23 ± 0.01	0.18 ± 0.05	0.15 ± 0.06^e

Data are presented as mean ± SD (n = 4 per group). IV, intravenous; SC, subcutaneous. Significant difference compared with baseline: ^* p < 0.05, ^** p < 0.01. Significantly different, with p < 0.001: ^aall regions (except for right striatum), ^ball regions (except for left striatum), ^ccompared to all other brain regions, ^dall regions (except for the posterior cortical area), or ^eall regions (except for the frontal cortical area).